Liminal BioSciences, Inc.

Liminal BioSciences, Inc.

Liminal BioSciences, Inc.

Date Founded



440 Armand-Frappier Boulevard,Suite 300,Laval, QC H7V 4B4

Type of Company


Employees (Worldwide)



Medical Products & Equipment

Company Description

Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Bioseparations, Plasma-derived Therapeutics, and Small Molecule Therapeutics. The Bioseparations segment offers prometic's core bioseparation technologies and products. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The Small Molecule Therapeutics segment manufactures drug candidates such as PBI-4050, PBI-4547, and PBI-4425. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.

Contact Data
Trying to get in touch with decision makers at Liminal BioSciences, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

General Counsel

Chief Talent Officer

Chief Operating Officer-International

Head of Regulatory Affairs & Quality Assurance

Chief Operating Officer, North America

Senior Vice President of Product & Asia-Pacific Development Prometic BioTherapeutics Inc

Senior Vice President, Product & Asia/Pacific Development

Vice President, Product Development, Quality & Regulatory Affairs

Board of Directors

Chief Investment Officer & Managing Director at Thomvest Asset Management, Inc.

Chief Executive Officer at Liminal BioSciences, Inc.

Director at Thomvest Asset Management, Inc.

Executive Vice President, Business Operations & Chief Financial Officer at Zymeworks, Inc.

Visiting Professor of Medicine at University of Edinburgh Medical School

Former Attorney at Gowling Lafleur Henderson LLP

General Partner at Five Corners Capital, Inc.

Paths to Liminal BioSciences, Inc.
Potential Connections via
Relationship Science
Liminal BioSciences, Inc.
Recent Transactions
Details Hidden

KKR & Co., Inc., Kohlberg Kravis Roberts & Co. LP purchase Prometic Bioseparations Ltd. from Liminal BioSciences, Inc.

Details Hidden

Liminal BioSciences, Inc. issued CAD Common Shares - Bought Deal

Details Hidden

Liminal BioSciences, Inc. purchases Telesta Therapeutics, Inc.

Transaction Advisors

Advised onLiminal BioSciences, Inc. issued Common Stock


Advised onLiminal BioSciences, Inc. issued Common Stock


Advised onLiminal BioSciences, Inc. issued Common Stock

Executive Vice Chair & Managing Director, Institutional Fixed Income

Advised onLiminal BioSciences, Inc. issued Common Stock


Advised onLiminal BioSciences, Inc. issued Common Stock


Advised onLiminal BioSciences, Inc. issued Common Stock


Octapharma AG develops, produces and sells plasma related products for treatment in coagulation disorders and immune diseases. The firm's products include virus-inactivated plasma for transfusion and fractionation products such as coagulation Factors VIII & IX for the treatment of haemophilia, von Willebrand Factor concentrate, prothrombin complex concentrate and immunoglobulins. Octapharma was founded in 1983 and is headquartered in Lachen, Switzerland.

Key Stats and Financials As of 2018
Market Capitalization
Total Enterprise Value
Earnings Per Share
Total Equity
Total Debt
Enterprise Value Sales
Net Profit
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Five Year Compounded Annual Growth Rate Of Revenue
Details Hidden

AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.

Details Hidden

Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications.Arriva's current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals - Ingelheim am Rhein, RP

C.H. Boehringer Sohn AG & Co. KG is a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus (HIV) infection and cancer. The company was founded on April 4, 1894 and is headquartered in Ingelheim am Rhein, Germany.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Liminal BioSciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Liminal BioSciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Liminal BioSciences, Inc..